Skip to content
Menu
Pharmaceutical News
Pharmaceutical Media Releases
About
Contact
Syntrix Completes Initial SX-682 Dosing in Broad Phase 1/2 Cancer Trial Campaign Now Encompassing 5 Solid Cancer Types Plus Myelodysplastic Syndromes
27 Oct 2020